Treatment-ResistantSchizophrenia: TreatmentResponse and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

American Journal of Psychiatry

Volumn 174, Issue 3, 2017, Pages 216-229

  Howes, Oliver D ^a   McCutcheon, Rob ^a   Agid, Ofer ^a   De Bartolomeis, Andrea ^a   Van Beveren, Nico J M ^a   Birnbaum, Michael L ^a   Bloomfield, Michael A P ^a   Bressan, Rodrigo A ^a   Buchanan, Robert W ^a   Carpenter, William T ^a   Castle, David J ^a   Citrome, Leslie ^a   Daskalakis, Zafiris J ^a   Davidson, Michael ^a   Drake, Richard J ^a   Dursun, Serdar ^a   Ebdrup, Bjørn H ^a   Elkis, Helio ^a   Falkai, Peter ^a   Fleischacker, W Wolfgang ^a   Gadelha, Ary ^a   Gaughran, Fiona ^a   Glenthøj, Birte Y ^a   Graff Guerrero, Ariel ^a   Hallak, Jaime E C ^a   Honer, William G ^a   Kennedy, James ^a   Kinon, Bruce J ^a   Lawrie, Stephen M ^a   Lee, Jimmy ^a   Leweke, F Markus ^a   MacCabe, James H ^a   McNabb, Carolyn B ^a   Meltzer, Herbert ^a   Möller, Hans Jürgen ^a   Nakajima, Shinchiro ^a   Pantelis, Christos ^a   Marques, Tiago Reis ^a   Remington, Gary ^a   Rossell, Susan L ^a   Russell, Bruce R ^a   Siu, Cynthia O ^a   Suzuki, Takefumi ^a   Sommer, Iris E ^a   Taylor, David ^a   Thomas, Neil ^a   Üçok, Alp ^a   Umbricht, Daniel ^a   Walters, James T R ^a   Kane, John ^a   Correll, Christoph U ^a   more..

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; CONSENSUS; DISEASE DURATION; DISEASE SEVERITY; FUNCTIONAL DISEASE; HUMAN; NOMENCLATURE; PRACTICE GUIDELINE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESISTANCE IN PSYCHOSIS; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT RESPONSE; BRIEF PSYCHIATRIC RATING SCALE; CONSENSUS DEVELOPMENT; DRUG RESISTANCE; PSYCHOLOGY; PSYCHOMETRY; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DRUG RESISTANCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 85014440556     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16050503     Document Type: Article

References (93)

1. Howes OD, MurrayRM: Schizophrenia: Anintegratedsociodevelopmentalcognitive model. Lancet 2014; 383: 1677-1687
2. López-Muñoz F, Alamo C, Cuenca E, et al: History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005; 17: 113-135
3. Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377-384
4. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatmentresistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
5. National Institute for Health and Care Excellence (NICE): Psychosis and schizophrenia in adults: Prevention and management (NICE guideline CG178). London, NICE, Feb 12, 2014 (http: //www.nice. org.uk/guidance/cg178)
6. Lehman AF, Lieberman JA, Dixon LB, et al: Practice Guideline for the Treatment of Patients With Schizophrenia, second edition. Am J Psychiatry 2004; 161(Feb suppl): 1-56
7. Falkai P, Wobrock T, Lieberman J, et al: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132-191
8. Correll CU, Kishimoto T, Nielsen J, et al: Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther 2011; 33: B16-B39
9. Suzuki T, Remington G, Mulsant BH, et al: Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophr Res 2011; 133: 54-62
10. Samara MT, Dold M, Gianatsi M, et al: Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis. JAMA Psychiatry 2016; 73: 199-210
11. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multipletreatments meta-analysis. Lancet 2013; 382: 951-962
12. Bitter I, Dossenbach MRK, Brook S, et al: Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 173-180
13. Buchanan RW, Ball MP, Weiner E, et al: Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry 2005; 162: 124-129
14. Kane JM, Correll CU: The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry 2016; 73: 187-188
15. Purcell H, Lewis S: Postcode prescribing in psychiatry: Clozapine in an English county. Psychiatr Bull 2000; 24: 420-422
16. Howes OD, Vergunst F, Gee S, et al: Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-485
17. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812
18. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
19. Leucht S, Samara M, Heres S, et al: Dose equivalents for secondgeneration antipsychotics: The minimum effective dose method. Schizophr Bull 2014; 40: 314-326
20. Leucht S, Samara M, Heres S, et al: Dose equivalents for secondgeneration antipsychotic drugs: The classical mean dose method. Schizophr Bull 2015; 41: 1397-1402
21. Gardner DM, Murphy AL, O'DonnellH, et al: International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693
22. Leucht S, Samara M, Heres S, et al: Dose equivalents for antipsychotic drugs: The DDD method. Schizophr Bull 2016; 42(suppl 1): S90-S94
23. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39: 1-30
24. Barnes TR: Schizophrenia Consensus Group of British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620
25. Taylor D, Paton C, Kapur S: The Maudsley Prescribing Guidelines, in Psychiatry. Chichester, UK, John Wiley & Sons, 2015
26. VermaS, ChanLL, CheeKS, et al: Ministry of Health clinical practice guidelines: Schizophrenia. Singapore Med J 2011; 52: 521-525
27. Andreasen NC: Scale for the Assessment of Negative Symptoms. Iowa City, University of Iowa, 1984
28. Andreasen NC: Scale for the Assessment of Positive Symptoms. Iowa City, University of Iowa, 1984
29. Bell M, Milstein R, Beam-Goulet J, et al: The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: Reliability, comparability, and predictive validity. J Nerv Ment Dis 1992; 180: 723-728
30. Levaux MN, Potvin S, Sepehry AA, et al: Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. Eur Psychiatry 2007; 22: 104-115
31. Keefe RSE, Goldberg TE, Harvey PD, et al: The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparisonwith a standard neurocognitive battery. Schizophr Res 2004; 68: 283-297
32. Leucht S, Kane JM, Etschel E, et al: Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology 2006; 31: 2318-2325
33. Leucht S: Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 2014; 75(suppl 1): 8-14
34. Haro JM, Kamath SA, Ochoa S, et al: The Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; 107: 16-23
35. ObermeierM, Schennach-Wolff R, Meyer S, et al: Is the PANSS used correctly? A systematic review. BMC Psychiatry 2011; 11: 113
36. Howes OD, Shotbolt P, BloomfieldM, et al: Dopaminergic function in the psychosis spectrum: An [18F]-DOPA imaging study in healthy individualswith auditoryhallucinations. SchizophrBull 2013;39: 807-814
37. Sommer IEC, Daalman K, Rietkerk T, et al: Healthy individuals with auditory verbal hallucinations: who are they? Psychiatric assessments of a selected sample of 103 subjects. Schizophr Bull 2010; 36: 633-641
38. Goodman SH, Sewell DR, Cooley EL, et al: Assessing levels of adaptive functioning: The Role Functioning Scale. Community Ment Health J 1993; 29: 119-131
39. Morosini PL, Magliano L, Brambilla L, et al: Development, reliability, and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101: 323-329
40. Baier M: Insight in schizophrenia: A review. Curr Psychiatry Rep 2010; 12: 356-361
41. Meltzer HY: Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 563-565
42. Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 158-169
43. Jones SH, Thornicroft G, Coffey M, et al: A brief mental health outcome scale: Reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654-659
44. Agid O, Arenovich T, Sajeev G, et al: An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72: 1439-1444
45. Kolakowska T, Williams AO, Ardern M, et al: Schizophrenia with good and poor outcome, I: Early clinical features, response to neuroleptics, and signs of organic dysfunction. Br J Psychiatry 1985; 146: 229-239
46. Wiersma D, Nienhuis FJ, Slooff CJ, et al: Natural course of schizophrenic disorders: A 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998; 24: 75-85
47. Emsley R, Nuamah I, Hough D, et al: Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012; 138: 29-34
48. Emsley R, Oosthuizen P, Koen L, et al: Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol 2013; 33: 80-83
49. Lieberman JA, Phillips M, Gu H, et al: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003
50. Girgis RR, Phillips MR, Li X, et al: Clozapine v chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry 2011; 199: 281-288
51. Sheitman BB, LiebermanJA: The naturalhistory and pathophysiology of treatment resistant schizophrenia. J PsychiatrRes 1998; 32: 143-150
52. Agid O, Kapur S, Arenovich T, et al: Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60: 1228-1235
53. Brissos S, Veguilla MR, Taylor D, et al: The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal. Ther Adv Psychopharmacol 2014; 4: 198-219
54. Citrome L: New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother 2013; 13: 767-783
55. HowesOD, Egerton A, Allan V, et al: Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550-2559
56. Zhang J-P, Gallego JA, Robinson DG, et al: Efficacy and safety of individual second-generation vs first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16: 1205-1218
57. Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163: 743-745
58. Frogley C, Taylor D, DickensG, et al: A systematic reviewof the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 2012; 15: 1351-1371
59. Fakra E, Azorin J-M: Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother 2012; 13: 1923-1935
60. Van Sant SP, Buckley PF: Pharmacotherapy for treatment-refractory schizophrenia. Expert Opin Pharmacother 2011; 12: 411-434
61. Essali A, Al-Haj Haasan N, Li C, et al: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009; (1): CD000059
62. Kane JM, Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71: 1115-1124
63. Mauri MC, Volonteri LS, Dell'Osso B, et al: Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 2003; 23: 660-664
64. Schulte P: What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003; 42: 607-618
65. Bell R, McLaren A, Galanos J, et al: The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 1998; 32: 567-574
66. Cooper TB: Clozapine plasma level monitoring: Current status. Psychiatr Q 1996; 67: 297-311
67. Jann MW, Grimsley SR, Gray EC, et al: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24: 161-176
68. Remington G, Agid O, Foussias G, et al: Clozapine and therapeutic drug monitoring: Is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 2013; 225: 505-518
69. Leucht S, Komossa K, Rummel-Kluge C, et al: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-163
70. Beck K, Howes O: Optimising treatment of refractory schizophrenia. Psychopharmacology (Berl) 2013; 227: 373-374
71. Breier A, Buchanan RW, Irish D, et al: Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 1145-1149
72. Meltzer HY, Bastani B, Kwon KY, et al: A prospective study of clozapine in treatment-resistant schizophrenic patients, I: Preliminary report. Psychopharmacology (Berl) 1989; 99(suppl): S68-S72
73. Lieberman JA, Safferman AZ, Pollack S, et al: Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-1752
74. Sherwood M, Thornton AE, Honer WG: A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. J Psychopharmacol 2012; 26: 1175-1184
75. Rosenheck R, Evans D, Herz L, et al: Howlong to wait for a response to clozapine: A comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 1999; 25: 709-719
76. Conley RR, Carpenter WT Jr, Tamminga CA: Time to clozapine responsein a standardized trial. Am J Psychiatry 1997; 154: 1243-1247
77. Fabrazzo M, La Pia S, Monteleone P, et al: Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002; 27: 1050-1055
78. McCutcheon R, Beck K, Bloomfield MAP, et al: Treatment resistant or resistant totreatment?Antipsychoticplasmalevels inpatientswithpoorly controlled psychotic symptoms. J Psychopharmacol 2015; 29: 892-897
79. Kane JM, Kishimoto T, Correll CU: Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors, and management strategies. World Psychiatry 2013; 12: 216-226
80. Velligan DI, Wang M, Diamond P, et al: Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007; 58: 1187-1192
81. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al: Medication adherence in outpatients with severemental disorders: Relation between self-reportsandserumlevel. JClinPsychopharmacol 2010; 30: 169-175
82. Besch CL: Compliance in clinical trials. AIDS 1995; 9: 1-10
83. McGorry PD, Yung AR, Phillips LJ, et al: Randomizedcontrolled trial of interventions designed to reduce the risk of progression to firstepisode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928
84. Hiemke C, Baumann P, Bergemann N, et al: AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
85. Mullard A: Do you want chips with that? Nat Rev Drug Discov 2015; 14: 735-737
86. Suzuki T, Remington G, Mulsant BH, et al: Defining treatmentresistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Res 2012; 197: 1-6
87. Lee J, Takeuchi H, Fervaha G, et al: Subtyping schizophrenia by treatment response: Antipsychotic development and the central role of positive symptoms. Can J Psychiatry 2015; 60: 515-522
88. Huhn M, Tardy M, Spineli LM, et al: Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry 2014; 71: 706-715
89. Howes OD, Kapur S: A neurobiological hypothesis for the classification of schizophrenia: Type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry 2014; 205: 1-3
90. Demjaha A, Murray RM, McGuire PK, et al: Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203-1210
91. Demjaha A, Egerton A, Murray RM, et al: Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014; 75: E11-e13
92. Lenior ME, Dingemans PM, Linszen DH, et al: Social functioning and the course of early-onset schizophrenia: Five-year follow-up of a psychosocial intervention. Br J Psychiatry 2001; 179: 53-58
93. Häfner H, Maurer K, Löffler W, et al: Modeling the early course of schizophrenia. Schizophr Bull 2003; 29: 325-340